To Explore the Effectiveness of Jing-Si Herbal Tea Against Non-alcoholic Fatty Liver Disease

Taichung Tzu Chi Hospital108 enrolled

Overview

The aim of this study is to explore the effectiveness of Jing-Si Herbal Tea on improving the Non-alcoholic fatty liver disease patients

This study adopted a randomized double-blind design, 2-arm trial study. All eligible patients included in the study agreed to participated and signed the informed consent from and the study procedures were approved by the ethical committee of Taichung Tzu Chi general hospital (REC110-74). Patients were recruited from the Gastroenterology department of Taichung Tzu Chi hospital. After random assignment to 2 groups, patients will receive Jing-Si Herbal Tea or placebo twice a day for 24 weeks. We will evaluate the blood test results, abdominal ultrasound and physical examination every 12 weeks.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

TRIPLE

Enrollment

108

Conditions

Non-alcoholic Fatty Liver Disease

Interventions

Jing-Si Herbal TeaOTHER

patient will receive twice in a day for 24 weeks

Placebo Jing-Si Herbal TeaOTHER

Placebo Jing-Si Herbal Tea

Eligibility

Sex: ALLMin age: 20 YearsMax age: 70 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Sign the Informed consent * Age between 20-70 * Diagnosis for moderated NAFLD * Liver disease without hepatic decompensation * HbA1c \< = 8.0 % Exclusion Criteria: * Do not sign the Informed consent * Other related liver diseases will affect the study which evaluated by physicians * Women of potential pregnancy or pregnant women

Locations (1)

Taichung Tzu Chi Hospital

Taichung, Taiwan, Taiwan

Outcomes

Primary Outcomes

Assessing the changes from baseline blood glucose at 24 week

Collect the data of blood glucose from blood test

Time frame: 24 week

Assessing the changes from baseline GOT (Glutamic Oxaloacetic Transaminase) at 24 week

Collect the data of GOT from blood test

Time frame: 24 week

Assessing the changes from baseline GPT (Glutamic Pyruvic Transaminase) at 24 week

Collect the data of GPT from blood test

Time frame: 24 week

Assessing the changes from baseline total cholesterol at 24 week

Collect the data of total cholesterol from blood test

Time frame: 24 week

Assessing the changes from baseline triglycerides at 24 week

Collect the data of triglycerides from blood test

Time frame: 24 week

Assessing the changes from baseline HDL-C at 24 week

Collect the data of HDL-C from blood test

Time frame: 24 week

Assessing the changes from baseline LDL-C at 24 week

Collect the data of LDL-C from blood test

Time frame: 24 weekk

Assessing the changes from baseline NAFLD activity at 24 week

Scoring the level of NAFLD activity

Time frame: 24 week

Assessing the changes from baseline BMI at 24 week

Collect the body height and body weight, weight and height will be combined to report BMI in kg/m\^2

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.